CNR Institutional Research Information System

AZZOLINA, ANTONINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.531
NA - Nord America 863
EU - Europa 382
SA - Sud America 289
Continente sconosciuto - Info sul continente non disponibili 34
AF - Africa 30
OC - Oceania 2
Totale 3.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 807
SG - Singapore 625
CN - Cina 354
BR - Brasile 227
HK - Hong Kong 211
VN - Vietnam 141
NL - Olanda 98
IT - Italia 94
FR - Francia 83
KR - Corea 50
IN - India 35
GB - Regno Unito 32
JP - Giappone 32
BD - Bangladesh 29
AR - Argentina 28
CA - Canada 26
DE - Germania 17
MX - Messico 15
EC - Ecuador 12
ID - Indonesia 11
ZA - Sudafrica 10
ES - Italia 9
FI - Finlandia 9
IL - Israele 7
CO - Colombia 6
IQ - Iraq 6
KE - Kenya 6
RU - Federazione Russa 6
JM - Giamaica 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
EG - Egitto 4
LT - Lituania 4
SA - Arabia Saudita 4
SE - Svezia 4
UY - Uruguay 4
AZ - Azerbaigian 3
IE - Irlanda 3
MA - Marocco 3
PE - Perù 3
PL - Polonia 3
PY - Paraguay 3
TR - Turchia 3
UZ - Uzbekistan 3
VE - Venezuela 3
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
KZ - Kazakistan 2
NP - Nepal 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UA - Ucraina 2
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
MM - Myanmar 1
NI - Nicaragua 1
NO - Norvegia 1
NR - Nauru 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
TG - Togo 1
Totale 3.097
Salva come PNG Salva come JPEG
Città #
Santa Clara 367
Singapore 360
Hong Kong 211
Hefei 117
San Jose 84
Beijing 77
Lauterbourg 65
Ho Chi Minh City 53
Seoul 49
Ashburn 46
Hanoi 25
Tokyo 25
Los Angeles 22
São Paulo 20
Dallas 19
New York 18
Mumbai 14
Buffalo 12
Palermo 10
Montreal 9
Orem 8
Frankfurt am Main 7
Haiphong 7
Portsmouth 7
Rio de Janeiro 7
Toronto 7
Bengaluru 6
Brasília 6
Council Bluffs 6
Helsinki 6
Houston 6
London 6
Mexico City 6
Minamishinagawa 6
Nairobi 6
Phoenix 6
Potenza 6
Biên Hòa 5
Brooklyn 5
Da Nang 5
Denver 5
Düsseldorf 5
Johannesburg 5
Milan 5
Quito 5
Thái Bình 5
Amsterdam 4
Belo Horizonte 4
Chennai 4
Kingston 4
Montevideo 4
Salvador 4
San José 4
Ankara 3
Atlanta 3
Baku 3
City of London 3
Dhaka 3
Dublin 3
Elk Grove Village 3
Forest City 3
Goiânia 3
Guayaquil 3
Lappeenranta 3
Lima 3
Manaus 3
Montes Claros 3
New Delhi 3
Newark 3
Ninh Bình 3
Poplar 3
Porto Alegre 3
Ribeirão Preto 3
San Francisco 3
Santo André 3
Santos 3
Stockholm 3
Tashkent 3
Acalanes Ridge 2
Anápolis 2
Aparecida de Goiânia 2
Aracaju 2
Aversa 2
Belém 2
Betim 2
Boardman 2
Bogotá 2
Bologna 2
Bratislava 2
Buenos Aires 2
Bình An 2
Bình Dương 2
Bắc Ninh 2
Cagliari 2
Cairo 2
Camaçari 2
Campinas 2
Caruaru 2
Chicago 2
Clorinda 2
Totale 1.904
Salva come PNG Salva come JPEG
Nome #
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 98
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 86
Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta 85
Cationic Solid-lipid nanoparticles as DNA carriers. 82
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 78
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma 68
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells 65
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 64
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 62
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 61
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 59
In vitro and in vivo antitumor activity of the proteasome inhibitor MLN2238 in hepatocellular carcinoma cells 59
Hepatocellular Carcinoma: A Difficult Cancer to Treat 56
GSK-3 in liver diseases: Friend or foe? 55
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 55
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 54
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 51
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 51
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 50
Development of nimesulide loaded solid lipid nanoparticles. 48
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 46
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 45
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 43
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells 43
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 42
The response to simulated hypogravity is dependent on the proliferation state and temperature in FRTL-5 thyroid cells 39
Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability 39
Substance P selectively activates TNF-a mRNA in rat uterine immune cells: a neuroimmune link 39
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 38
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 38
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 37
Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-a production 35
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 35
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 35
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
From targets to targeted therapies in Hepatocellular carcinoma 34
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 34
Molecular mechanisms of sorafenib action in liver cancer cells. 34
Cationic solid-lipid nanoparticles for gene delivery. 34
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 33
Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies 33
Microgravity and cellular homeostasis: effects of simulated hypogravity on FRTL-5 thyroid cells. 33
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells. 32
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery 31
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation 31
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells through redox-dependent signaling. 31
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 30
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 29
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 29
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 28
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells. 28
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells. 28
Gene expression profiling of human liver cancer cells following celecoxib treatment. 28
G. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 28
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 28
INVOLVEMENT OF p38 AND JNK mapks PATHWAYS IN SUBSTANCE P-INDUCED PRODUCTION OF TNF - BY PERITONEAL MAST CELLS 28
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 28
Solid-lipid nanoparticles for gene delivery to cells. 28
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 27
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 27
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 26
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 26
The multikinase inhibitor Sorafenib exhibits a strong cytotoxic effect in liver cancer cells through a MEK/ERK signaling-independent mechanism 26
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 25
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells 25
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 25
Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells 24
Substance P induces TNF-alpha and IL-6 production through NFkB in peritoneal mast cells 24
Growth suppression and apoptosis induction in human hepatoma cells by DHMEQ, a novel NF-KB inhibitor, is mediated through a ROS-dependent mechanism. 23
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 23
Microgravity and cellular homeostasis:effects of stimulated hypogravity on FRTL-5 thyroid cells. 23
Solid lipid nanoparticles (SLNs) containing nimesulide: preparation, characterization and in cytotoxicity studies 22
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells 22
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells. 21
Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies. 21
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 21
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 20
Synthesis and characterization of polyaminoacidic polycations for gene delivery. 20
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism 16
Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-α by peritoneal mast cells 16
Substance P induces TNF-α and IL-6 production through NFκB in peritoneal mast cells 15
Totale 3.131
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.359
article - articoli 6.102
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 314
Totale 16.775
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20248 0 0 0 0 0 0 0 0 0 0 4 4
2024/20251.227 8 5 81 48 301 68 8 82 29 116 275 206
2025/20261.820 126 192 182 307 309 58 218 138 125 84 44 37
2026/202776 76 0 0 0 0 0 0 0 0 0 0 0
Totale 3.131